Tissue Engineering and Regenerative medicine, empowered by Biofabrication technologies, hold the premises to provide solutions to unmet clinical needs, such as organ donor shortage or genetic diseases. These huge advancements are determining a changing scenario, with a quite confusing understanding about the steps toward the clinical translation of new researches and products, giving as result an overestimation or an underestimation of the required in vitro and in vivo tests for their validation. The proper definition and classification of the research products can be considered an action toward the refinement of animal experiments. An appropriate classification is crucial because the complications due to the combination of biological and non-biological materials need the application of specific rules. This paper aims at helping the academic and industrial community to clarify the identification and classification of their research products.
Introduction
Tissue Engineering and Regenerative medicine, empowered by Biofabrication technologies, hold the premises to provide solutions to unmet clinical needs, such as organ donor shortage or genetic diseases. 1 Bioprinting scaffolds or other implants are changing not only the surgical procedures, but also the organization of hospitals, which can potentially produce in-house these products. 2 In this context, new biomaterials but also bioprinters and bioreactors are reaching the market. Figure 1 shows the several areas in the bioprinting healthcare scenario.
These huge advancements are determin-ing a changing scenario, with a quite confusing understanding about the steps toward the clinical translation of new researches and products, giving as result an overestimation or an underestimation of the required in vitro and in vivo test for their validation.
Materials and Methods
The proper definition and classification of the research products can be considered an action toward the refinement of animal experiment. For example, generic term "scaffold" is used to indicate an implantable substrate, which can be correctly classified as Medical Device (MD) or as Advanced Therapy Medicinal Product (ATMP) according to its working principles and/or components. Similarly, bioprinters are normally used to fabricate scaffolds or in vitro model for biological experiment, but they could potentially be used to bioprint in situ biomaterial inks and bionks: in this case, they have to be considered as MD, with the proper request of safety and efficacy. At European level, these requirements are defined by the EU Regulation 2017/745 and 1394/2007, which set the legislative framework for the definition and validation toward commercialization of MDs and ATMPs, respectively. 3, 4 
Results
With the aim at helping the academic and industrial community to clarify the identification and classification of their research products, Figure 2 tries to clarify these differences with practical examples.
Conclusions
Bioprinting raises questions about the exact legal nature and specific classification of bioprinted-related products. An appropriate classification is crucial, in particular, because the complications due to the combination of biological and non-biological materials need the application of specific rules. This suggests that the additive manufacturing technologies applied to bioprinting need an appropriate legal framework in particular in the domain of pharmaceutical, medical devices, advances therapies, tissues and cells where significant regulatory and socio-ethical challenges are faced. 
